Roivant Sciences Ltd. Files 8-K

Ticker: ROIV · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1635088

Sentiment: neutral

Topics: corporate-disclosure, 8-k

TL;DR

Roivant Sciences filed an 8-K on 12/11/25 with updated corporate info.

AI Summary

Roivant Sciences Ltd. filed an 8-K on December 11, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom, and provides a contact phone number of +44 207 400-3347. The company is incorporated in Bermuda and its fiscal year ends on March 31.

Why It Matters

This 8-K filing provides updated corporate information and disclosures for Roivant Sciences Ltd., which is important for investors and stakeholders to stay informed about the company's official reporting.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report for Roivant Sciences Ltd., primarily covering Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K report filed?

The report was filed on December 11, 2025.

Where are Roivant Sciences Ltd.'s principal executive offices located?

The principal executive offices are located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom.

What is Roivant Sciences Ltd.'s state of incorporation?

Roivant Sciences Ltd. is incorporated in Bermuda.

What is the fiscal year end for Roivant Sciences Ltd.?

The fiscal year end for Roivant Sciences Ltd. is March 31.

Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 9 · Accepted 2025-12-11 07:46:57

Key Financial Figures

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On December 11, 2025, Roivant Science Ltd. (the "Company") issued a press release in connection with the Company's 2025 Investor Day. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Also on December 11, 2025, the Company posted the presentation to be used in connection with its 2025 Investor Day on the "Events & Presentations" page of its investor relations website at https://investor.roivant.com. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company's website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press release dated December 11, 2025. 99.2 Presentation dated December 11, 2025. 104 Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory Dated: December 11, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing